MedicAlert is making the Signature Genetics drug reaction test available to its members across the US with the help of Seryx. Terms of the agreement were not disclosed.
The test allows physicians to customize drug prescriptions based on an individual patient’s genetic make-up. The test also identifies drug combinations that can cause potentially harmful interactions.
Signature Genetics matches the individual patient’s DNA test results against their drug regimen and the scientific literature to produce a personalized report, provided by Seryx. The report identifies how an individual will metabolize or process medications and indicates potential serious adverse reactions to many of the most commonly prescribed drugs.
The report reviews current medications and highlights future medications that are better suited to the patient’s particular genetic make-up. A copy of the report is stored in the member’s electronic health record in the secure MedicAlert repository, and if requested by the member, a copy can be sent to their designated physician.
“Together with MedicAlert, our Signature Genetics Report will provide scientifically validated interpretive information and guidance for their members and the medical profession to optimize drug therapy and minimize drug- related adverse events,” said Patrick Rambaud, president and CEO of Seryx.